Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

gemcitabine liposome FF-10832

A liposomal formulation in which gemcitabine, a broad-spectrum antimetabolite and deoxycytidine analogue, is encapsulated in liposomes, with potential antineoplastic activity. Upon administration of gemcitabine liposome FF-10832, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA, resulting in premature termination of DNA replication and the induction of tumor cell apoptosis. In addition, dFdCDP inhibits ribonucleotide reductase (RNR) and reduces the deoxynucleotide pool available for DNA synthesis. This inhibits tumor cell proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:liposomal gemcitabine FF-10832
Code name:FF 10832
FF-10832
FF10832
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search